Literature DB >> 17301418

Evaluation of In Vitro Production of IFN-gamma, IL-10, IL-12 and IL-13 by Blood Cells in Patients with Cutaneous Leishmaniasis Lesions.

Majid Mahmoodi1, Saeid Rajabalian, Alireza Fekri, Iraj Esfandiarpour.   

Abstract

This study investigated the in vitro production of interferon-gamma, interleukin (IL)-10, IL-12, and IL-13, after antigenic stimulation of the cells (with Leishmania antigen and lipopolysaccharide) using whole blood from patients with cutaneous leishmaniasis lesions caused by Leishmania tropica and in normal volunteers with history of cutaneous leishmaniasis.ELISA results showed that the mean production of interferon-gamma by cells of whole blood in patients with lesions in response to Leishmania antigen was significantly lower than corresponding values in volunteers with history of cutaneous leishmaniasis (P< 0.05) and significantly higher levels of IL-10 production in patients with lesions were observed compared with cured volunteers of the disease (P<0.01). A similar level of IL-12, including p40 subunit of IL-12, was detected in both groups tested in this study in response to stimulation of parasite antigen. The levels of the IL-13 after stimulation with Leishmania antigen were significantly more in patients compared with volunteers with history of cutaneous leishmaniasis (P< 0.01). There was no significant difference in the mean production of IFN-gamma, IL-10, IL-12 and IL-13 by PHA or LPS stimulated cells from patients with lesions and volunteers with history of the disease, indicating that there was no qualitative defect in cytokine production in these patients.In this study, we have detected the decreased production of interferon- gamma by cells of patients with lesions of cutaneous leishmaniasis in response to parasite antigen and unbalanced production of regulatory cytokines such as IL-10 and IL-13 using the whole-blood stimulation assay technique. The required small volume of blood and the rapid set up time are the advantages in this assay technique. Using this assay for further immunodetection of cytokines may confirm its value for clinical investigation.

Entities:  

Year:  2005        PMID: 17301418     DOI: 04.01/ijaai.1521

Source DB:  PubMed          Journal:  Iran J Allergy Asthma Immunol        ISSN: 1735-1502            Impact factor:   1.464


  6 in total

1.  IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.

Authors:  Nasim Akhtar Ansari; Rajiv Kumar; Shalini Gautam; Susanne Nylén; Om Prakash Singh; Shyam Sundar; David Sacks
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

Review 2.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

3.  Identification of leishmania isolates from healing and nonhealing cutaneous leishmaniasis patients using internal transcribed spacer region PCR.

Authors:  Sepideh Tolouei; Seyed Hossein Hejazi; Kamran Ghaedi; Seyed Javad Hasheminia
Journal:  Jundishapur J Microbiol       Date:  2014-04-01       Impact factor: 0.747

4.  Immune Responses in Cutaneous Leishmaniasis: In vitro Thelper1/Thelper2 Cytokine Profiles Using Live Versus Killed Leishmania major.

Authors:  Akram Miramin-Mohammadi; Amir Javadi; Seyyed Ebrahim Eskandari; Mahmood Nateghi-Rostami; Ali Khamesipour
Journal:  J Arthropod Borne Dis       Date:  2021-03-31       Impact factor: 1.198

5.  IL-23 and IL-27 Levels in Macrophages Collected from Peripheral Blood of Patients with Healing Vs Non-Healing Form of Cutaneous Leishmaniasis.

Authors:  S Tolouei; K Ghaedi; A Khamesipour; M Akbari; M Baghaei; Sj Hasheminia; M Narimani; Sh Hejazi
Journal:  Iran J Parasitol       Date:  2012       Impact factor: 1.012

6.  Comparison of cytokine profile of IFN-γ, IL-5 and IL-10 in cutaneous leishmaniasis using PBMC vs. whole blood.

Authors:  Akram Miramin Mohammadi; Amir Javadi; Alireza Firooz; Ali Khamesipour
Journal:  Iran J Microbiol       Date:  2019-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.